Want to join the conversation?
On July 25, 2016, $ABBV jointly announced a clinical collaboration with $BMY to evaluate the combination of Rova-T with BMS' immuno-oncology agents in small cell lung cancer, with trails beginning this year. This combination brings innovative new therapies forward that have the potential to significantly improve the survival of patients.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.